MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: BioPharmaceuticals _ Orphan & Rare Diseases
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)*
Organization & Developments: Corbus
Parents
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)*
Children
*Corbus Pharmaceuticals Holdings, Inc. is a clinical-stage pharmaceutical company focused on the development and commercialization of therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates.
2017: Corbus Pharmaceuticals: Anabasum Is A Pipeline In And Of Itself - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
2018: Corbus Pharma reels in $25M to pay for its PhIIb cystic fibrosis study, shares sink – Endpoints News
2018: Corbus Pharmaceuticals Presents Big Risk And Big Reward_seekingalpha.com
2018: Corbus_2 Attractive Biotech Stocks Under $10
2018: Corbus: Revisiting This ~$5 Biotech Concern - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
2019: Corbus And Lenabasum In Systemic Sclerosis, And The Market Assessment_seekingalpha.com
2019: Corbus Has Ties To Suspect Investors And A History Of Failed Clinical Trials For Lenabasum - Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP)
2020: Corbus to ax half of staff after back-to-back trial failures
2020: Corbus' Lenabasum Fails Phase III Trial for Systemic Sclerosis
2020: Revisiting Corbus Pharmaceuticals_seekingalpha.com
2024: Corbus Pharmaceuticals Holdings, Inc. (CRBP): This Small-Cap Healthcare Stock Is A Good Buy Right Now
2024: Corbus Pharmaceuticals: A Pause In The Rally Likely
2024: Corbus Pharmaceuticals: Surging On The Back Of Great News, But I See Dark Clouds
2024: Corbus Pharmaceuticals' Sell-Off: Speculative Entry Price In Oncology And Obesity Therapies
2024: Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug
2024: Neutral On Corbus Pharmaceuticals' Financials And Clinical Progress In Oncolog
2024: We're Not Very Worried About Corbus Pharmaceuticals Holdings' (NASDAQ:CRBP) Cash Burn Rate
2024: With 59% ownership, Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) boasts of strong institutional backing
Jumps
*Key People: Corbus
Finance & Acquisitions: Corbus